Myocardial perfusion and metabolism after transcoronary ablation of septum hypertrophy (TASH) in hypertrophic obstructive cardiomyopathy;Myokardiale perfusion und metabolismus nach transkoronarer ablation der septumhypertrophie (TASH) bei hypertrophisch obstruktiver kardiomyopathie

NuklearMedizin

Volumn 36, Issue 6, 1997, Pages 218-222

  Lerch, H ^a   Schafers M ^a   Gietzen, F ^a   Schafers K ^a   Kuwert, T ^a   Kuhn, H ^a   Schober, O ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Hypertrophic Obstructive Cardiomyopathy; Positron Emission Tomography; Single Photon Emission Tomography; Transcoronary Ablation of Septum Hypertrophy

Indexed keywords

ALCOHOL; FLUORODEOXYGLUCOSE F 18; GLUCOSE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; ARTICLE; CASE REPORT; GLUCOSE METABOLISM; HEART MUSCLE PERFUSION; HEART OUTFLOW TRACT OBSTRUCTION; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0030774649     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1629743     Document Type: Article

References (10)

1. Gietzen F, Leuner C, Gerenkamp T, Kuhn H. Abnahme der Obstruktion bei hypertrophischer Kardiomyopathie wahrend passagerer Okklusion des ersten Septalastes der linken Koronararterie. Z Kardiol 1994; 83 (abstr suppl 1): 146.
2. Gietzen F, Leuner C, Gerenkamp T, Kuhn H. Relief of obstruction in hypertrophic cardiomyopathy by transient occlusion of the first septal brach of the left coronary artery. Eur Heart J 1994; 15 (abstr suppl): 125.
3. Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaortic septal ischemia to reduce obstruction in hypertrophic cardiomyopathy: studies to develope a new catheterbased concept of treatment. Eur Heart J: in press.
4. Sigwart U Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-4.
5. Gietzen F, Leuner C, Gerenkamp T, Kuhn H. Katheterinterventionelle Therapie der hypertrophischen obstruktiven Kardiomyopathie durch Alkoholablation des ersten Septalastes der linken Koronararterie. Z Kardiol 1996; 85 (abstr suppl 2): 3.
6. Gleichmann U, Seggewiß H, Faber L et al. Kathetertherapie der hypertrophen obstruktiven Kardiomyopathie. Dtsch med Wschr 1996; 121: 679-85.
7. Gietzen F, Leimer C, Gerenkamp T, Kuhn H. Transcoronary ablation of septal hypertrophy. A new catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Circulation 1996; 94 (suppl, I): 1-84.
8. Ferrannini E, Santoro D, Bonadonna R et al. Metabolic and hemodynamic effects of insulin on human hearts. Am J Physiol 1993; 264-E308-15.
9. Schafers K, Schafers M, Lerch H, Biedenstein S, Stegger L, Kuwert T, Matheja P, Schober O. Normierte, räumliche Darstellung des myokardialen Glukose-Metabolismus (F-18-FDG-PET) und der myokardialen Perfusion (Tc-99m-MIBI-SPECT). Nuklearmedizin 1997; 36 (abstr): A54.
10. Gietzen F, Raute-Kreinsen U, Dellmann A et al. Pathologisch anatomische Veränderungen nach Transcoronarer Ablation der Septum-Hypertrophie (TASH) bei hypertrophisch obstruktiver Kardiomyopathie. Z Kardiol 1996; 85 (abstr suppl 5): 32.